Board Change

Ardana PLC
28 June 2007





                              ARDANA BOARD CHANGES


Edinburgh, UK, 28 June, 2007: Ardana, the company focused on improving human
reproductive health, today announces the appointment of Dr Chris Moyses to its
Board of Directors as a non-executive director and the retirement from the Board
of Ian Kent after seven years' service.  Both changes are with immediate effect.

Dr Moyses is a member of the Royal College of Physicians of London and is
currently Chief Medical Officer and director of Argenta Discovery Limited and
the non- executive chairman of Senexis Limited.  His previous positions include
Research and Development Director of Pharmagene plc, Chief Medical Officer and
director of Oxford GlycoSciences plc and Vice President of Clinical and
Regulatory Affairs at Amylin Europe.

Dr Moyses will also become a member of Ardana's Nominations and Corporate
Governance Committee, Audit Committee and Remuneration Committee.

With reference to paragraphs 9.6.13 (1)-(6) of the FSA's Listing Rules, there
are no other disclosures required.

Ian Kent joined the Ardana Board as a founder non executive director and
Chairman in 2000.  He relinquished the role of non executive Chairman in 2004.
Huw Jones replaces Ian as the Chairman of the Remuneration Committee.


Maureen Lindsay, CEO of Ardana, said:

'We are very grateful for the support and direction that Ian has given to Ardana
since its inception and we wish him every success for the future.  We welcome
Chris to Ardana.  He brings considerable pharmaceutical medical and regulatory
knowledge and experience to our Board that will be invaluable to us as we expand
our business and development product pipeline.'



For more information contact:

Ardana                                   Financial Dynamics
Maureen Lindsay                          (corporate/financial media relations)
Tel: + 44 (0) 131 226 8550               Julia Phillips/John Gilbert
                                         Tel: [phone]




About Ardana

Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $25.5
billion market.

Since its foundation, Ardana has maintained a broad and balanced portfolio to
manage risk and actively pursues product and technology in-licensing and
outlicensing to maintain a robust pipeline.


Ardana's lead products are summarised below:

  • Emselex(R), a once a day treatment for the symptoms of overactive bladder
    syndrome which Ardana has exclusive UK marketing and promotion rights and is
    being distributed in collaboration with Novartis UK Limited;
  • Striant(TM) SR, a testosterone replacement therapy that has been launched by
    Ardana through its own sales force in the UK and through marketing partners
    in certain European countries, as a treatment for men with confirmed
    hypogonadism;
  • Teverelix LA, in development for three initial indications (prostate
    cancer, benign prostatic hyperplasia and endometriosis);
  • Testosterone Cream, a trans dermal testosterone delivery system in
    development for the treatment of male hypogonadism, in Phase II trials;
  • Invicorp, an injectable combination drug treatment for erectile
    dysfunction, for which Ardana has marketing and manufacturing rights in
    Europe.
  • ARD-07 a growth hormone secretagogue in late stage development for the
    diagnosis of hormone deficiency


In addition, Ardana has a strong portfolio of follow-on products in development.
Ardana is listed on the Main Market of the London Stock Exchange.


For further information please see www.ardana.co.uk



                      This information is provided by RNS
            The company news service from the London Stock Exchange     
BOAOKOKBOBKDPAB